Targeting of myostatin (Mstn) activity or signalling has emerged as a potential strategy to combat obesity as deletion of Mstn is accompanied by a hypermuscular phenotype. The gene discussed is MSTN; the disease is obesity due to melanocortin 4 receptor deficiency.